Dotti G, Stella C C, Mangoni L, Cottafavi L, Caramatti C, Almici C, Rizzoli V
Department of Hematology, University of Parma, Italy.
Haematologica. 1995 Mar-Apr;80(2):142-5.
In this study, nine patients with non-Hodgkin's lymphoma (n = 6) and Hodgkin's disease (n = 3) receiving different cytotoxic chemotherapy regimens were given granulocyte colony-stimulating factor (G-CSF) (5 micrograms/kg/day) from 48 hours after the end of chemotherapy to 48 hours before the next chemotherapy administration. The decrease in mean absolute neutrophil counts (ANC) and in mean platelet (Plt) counts was not significant when pre-therapy counts were compared with post-therapy ones (p < 0.375 and p > 0.4, respectively). The mean actual dose intensity was 92% (range 68-100%). G-CSF treatment after chemotherapy reduces neutropenia and permits administration of the full chemotherapy program. A wash-out period between G-CSF treatment and chemotherapy administration is needed to prevent the detrimental effect of chemotherapy on leukocyte and platelet recovery when repeated cycles of cytotoxic drugs and G-CSF are administered.
在本研究中，9例接受不同细胞毒性化疗方案的非霍奇金淋巴瘤患者（n = 6）和霍奇金病患者（n = 3），在化疗结束后48小时至下次化疗给药前48小时给予粒细胞集落刺激因子（G-CSF）（5微克/千克/天）。将治疗前的平均绝对中性粒细胞计数（ANC）和平均血小板（Plt）计数与治疗后的计数进行比较时，ANC和Plt计数的下降并不显著（p分别<0.375和p>0.4）。平均实际剂量强度为92%（范围68 - 100%）。化疗后使用G-CSF可减轻中性粒细胞减少症，并允许实施完整的化疗方案。当重复给予细胞毒性药物和G-CSF的周期时，需要在G-CSF治疗和化疗给药之间设置一个洗脱期，以防止化疗对白细胞和血小板恢复产生不利影响。
